Natalizumab, an anti-integrin subunit α4 antibody, inhibited the adhesion of MM cells to non-cellular and cellular components of the microenvironment and reduced tumor growth, VEGF secretion and angiogenesis in an immunodeficient murine model [31]. The gene discussed is VEGFA; the disease is Miyoshi myopathy.